Improving outcomes for chronic pain patients on long-term opioid therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates three innovative interventions for individuals on long-term opioid therapy for chronic pain. It involves the initiation of low-dose transdermal buprenorphine without prior opioid withdrawal, a brief Cognitive Behavioral Intervention for pain, and accelerated repetitive Transcranial Magnetic Stimulation (rTMS) targeting the left dorsolateral prefrontal cortex. The study will assess clinical outcomes through standardized measures at various follow-up points to determine the safety and effectiveness of these approaches. The goal is to enhance pain management, reduce risks, and improve the quality of life for patients on opioid therapy.

Why it matters

Who can join: the full rules

Inclusion criteria:

Age \>/= 18 years

English-speaking

On LTOT, defined as taking prescription opioid therapy for 90 days or more

Past week average morphine equivalent dose (MED) \>/= 20mg

Willing and able to complete written informed consent

Willing and able to use a mobile/cell phone

Have at least one additional risk for opioid toxicity or overdose from the following list:

Opioid Toxicity or Overdose Risks:

1. Taking benzodiazepines with opioids
2. Substance Use Disorder diagnosis \[non-tobacco; Opioid Risk Tool\]

2\) Having ever experienced an overdose 4) Current major medical problem \[e.g. mod-severe liver disease, pancreatitis, chronic pulmonary disease, untreated sleep apnea, hospitalized for an acute medical issue in the past 6 months\]a,b 5) Response to BPI Item 8 \<30%, suggesting less than moderately clinically meaningful response to pain treatmentc 6) Co-morbid psychiatric diagnosis \[Opioid Risk Tool\] 7) Signs of opioid misuse \[any score \>0 on the following COMM Items: 3,4,5,9,10,11,14,15,16\] 8)Opioid Risk Tool \>3 or Current Opioid Misuse Measure ≥ 9 9) Struggling with any of the following side effects from opioids \[self-report\]

1. Dizziness and/or falls
2. Difficult-to-manage stomach pain, nausea, constipation or GI issues
3. Fatigue or low energy
4. Sleepiness or sedation
5. Trouble with memory or thinking clearly \[COMM Item 1\>0\]
6. Other troublesome side effect \[open answer\]

Exclusion criteria:

Known allergy to buprenorphine

Active moderate or severe substance use disorder with the exception of those listed below:

1. . Those with nicotine use disorder.
2. . Those meeting criteria for prescription opioid use disorder using only prescribed opioids will be considered on a case-by-case basis.

Cognitive disorder limiting ability to consent or fully participate in the brief cognitive intervention

Receiving methadone or buprenorphine treatment for OUD or pain

Taking naltrexone

Pregnancy

Currently incarcerated

Taking medications that prolong QTc interval, as determined by study investigators

Personal/immediate family history of Long QT Syndrome.

Significant or unstable condition/s or treatments that may impact safe participation in the study (as determined by the study investigators) such as significant cardiac condition (e.g. poorly-controlled heart failure, current or past cardiac arrhythmia, sustained systolic blood pressure \>180), significant metabolic disorder (e.g. labile diabetes, significant electrolyte abnormality), cancer (e.g. brain cancer, chemotherapy-induced cognitive impairment), major psychiatric disorder (e.g. active bipolar disorder, schizophrenia spectrum or other psychotic disorder, suicidal/homicidal intent within the past month, or any suicide attempts within the past year or current active suicidal ideation, as determined by medical clinician), developmental disorder (e.g. autism spectrum disorder, intellectual disability), or other neurologic disease (e.g. movement disorder, multiple sclerosis, moderate to severe brain injury).

Enrolled in a clinical trial or has received an investigational medication or device in the last 30 days.

TMS contraindications (e.g., ferromagnetic implants, conditions or treatments that lower seizure threshold, taking contraindicated medications, no identifiable motor threshold, as determined by study investigators).

Where it's running

• Medical University of South Carolina
  Charleston, South Carolina, United States Recruiting

Study contacts

• Principal investigator: Kelly Barth — Medical University of South Carolina
• Study coordinator: Kelly Barth
• Email: stephen@musc.edu
• Phone: 843-792-0686

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive Rehabilitation of Everyday Goals With GMT: How Different Ways of Delivery Work

  This study tests Goal Management Training to see if a Swedish version helps adults with acquired brain injury or chronic pain improve practical goal-directed thinking and daily functioning.

  Recruiting at 2 sites Karolinska Institutet · Luleå, Norrbotten County and 2 other locations · NCT07924774

• One-time Pain Reprocessing Therapy session for chronic pain at The Ottawa Hospital

  A single four-hour session of Pain Reprocessing Therapy is being tested to see if it can help adults with chronic pain feel better and have less pain.

  Recruiting Ottawa Hospital Research Institute · Ottawa, Ontario · NCT07919626

• Meaning-Based Psychotherapy for Adults with Chronic Pain

  This trial tests whether Meaning-Based Psychotherapy helps adults with chronic pain feel more purposeful, feel less depressed, and have a better quality of life compared with optimized usual care therapy.

  Recruiting Hospital Clinico Universitario San Cecilio · Granada, Granada · NCT07915440

• How chronic pain changes over time in kids with Duchenne Muscular Dystrophy

  This study is following children and teens with Duchenne Muscular Dystrophy for 6 months to see how their chronic pain changes and how it affects daily life.

  Recruiting Antalya Training and Research Hospital · Antalya, Antalya · NCT07892196

• CBD for Opioid Dependence and Pain on Buprenorphine

  This study tests whether different doses of cannabidiol (CBD) can affect pain and opioid cravings in adults with opioid use disorder who are on buprenorphine, using a short, randomized, placebo-controlled setup.

  Recruiting Early Phase 1 Yale University · West Haven, Connecticut · NCT07886606

• Cebranopadol for opioid withdrawal in adults with chronic pain

  This study tests whether cebranopadol can reduce withdrawal symptoms in adults with chronic pain who are physically dependent on prescribed opioids, compared with placebo.

  Recruiting at 2 sites Phase 2 Adneuris Therapeutics, Inc. · North Canton, Ohio and 1 other locations · NCT07874620

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.